Survival of Patients with Advanced Non-Small Cell Lung Cancer in Chonburi Cancer Hospital

International Agency for Research on Cancer. Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. [Internet]. 2012 [cited 2016 May 31]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_ population.aspx

Thepsuwan K, Martin N, Tanabodee J, editors. Hospital-based cancer registry. Chonburi. Kamolsilp Priting; 2012.

Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small celi lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311: 899-909.

Abratt RP, Hart GJ. 10-year update on chemotherapy for non-small cell lung cancer. Ann Onco 2006; 17 (5Suppl): S33–36

Schiller JH. Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparision of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-8.

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy - naive patients with advanced non–small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or Carboplatin– paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2010; 11: 121-8.

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 2012;13:239-46.

National Comprehensive Cancer Network. Clinical practice guideline in Oncology, Nonsmall cell lung cancer Version 4.2016. [Internet]. 2016. [cited 2016 May 31]. Available from: https://www.nccn.org/professionals/physician_ gls/pdf/nscl.pdf

Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. TNM Classification of Malignant Tumors. 7th ed. n.p. : Wiley-Blackwell; 2009

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.

Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.

Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM, et a. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 2010; 21: 540–7.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med 2006; 355:2542-50.

Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non–small-cell lung cancer. N Engl J Med 2010;363:733-42.

ASCO-ESMO Consensus statement on quality cancer care. J Clin Oncol 2006; 24: 3498-9.

Yamazaki K, Sugio K, Yamanaka T, Hirai F, Osoegawa A, Tagawa T, et al. Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following thirdgeneration chemotherapy. Antican Res 2010;30: 1311-6 .

Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5: 620-30.

Meili M, Baohui H, Shen J, Hao B, Hao J, Yizuo Z, et al. Prognostic factors in patients with stage IV non-small-cell lung cancer. J Thorac Oncol. 2007;2: S641 (P2-180).

Laohavinij S, Maneechavakajorn J. Prognostic factors for survival in advanced non-small cell lung cancer. J Med Assos Thai. 2004; 87: 1056-64.

Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900 -9.

Sequist LV, Joshi VA, Janne PA, Muzikansky A, Fidias P, Meyerson M, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007;12:90–8.

Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonald L, Galligioni A, et al. Prognostic and Predictive Implications of EGFR Mutations, EGFR Copy Number and KRAS Mutations in Advanced Stage Lung Adenocarcinoma. Antican Res 2010;30: 5121-8.

Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, Kang CH, et al. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non–small-cell lung cancer. J Thorac Oncol2013;8: 171-8.